AI Article Synopsis
Article Abstract
Purpose: The purpose of this study was to report a case of a patient with unilateral toxoplasma retinochoroiditis while on treatment with adalimumab, an anti-tumor necrosis factor α agent for ulcerative colitis.
Methods: This is a descriptive case report.
Results And Discussion: In addition to the patient with toxoplasma retinochoroiditis, there is one published report of two patients who developed toxoplasma chorioretinitis while on anti-tumor necrosis factor α therapy for rheumatoid arthritis: one was on adalimumab and methotrexate and the other one was on etanercept and methotrexate.
Conclusion: The authors need to be aware of this potentially vision threatening risk with anti-tumor necrosis factor α therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/ICB.0b013e3182790dbd | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A combination regimen of Intravitreal clindamycin with dexamethasone, systemic co-trimoxazole and steroids for macular Toxoplasma retinochoroiditis in immunocompetent cases.
Retina
January 2025
L V Prasad Eye Institute, GMR Varalaxmi Campus, Visakhapatnam, Andhra Pradesh, India.
Purpose: To study the role of intravitreal clindamycin with dexamethasone as an adjuvant to systemic co-trimoxazole and steroids in macular Toxoplasma retinochoroiditis.
Methods: Retrospective study of Toxoplasma retinochoroiditis cases from January 2014 to December 2021 treated with a combination of oral and intravitreal therapy in immunocompetent patients.
Results: 39 eyes of 39 patients were included in this study after meeting the inclusion criteria with the mean age of presentation being 25.
Concurrent Cilioretinal Artery Occlusion in Acute Toxoplasma Chorioretinitis.
Am J Ophthalmol
January 2025
Harvard Retinal Imaging Lab, Harvard Medical School, Boston, Massachusetts, USA; Retina Service, Massachusetts Eye and Ear, Boston, Massachusetts, USA. Electronic address:
Unilateral vitritis in an immunocompetent individual - A rare presentation of ocular toxoplasmosis.
Med J Malaysia
January 2025
Department of Ophthalmology, Saveetha Institute of Medical and Technical Sciences (Deemed to be University): SIMATS Deemed University, Chennai, Tamilnadu, India.
Ocular toxoplasmosis is the leading cause of infectious retinochoroiditis in both adults and children. It is caused by the obligate intracellular parasite, Toxoplasma gondii. It is a common cause of posterior uveitis and focal retinitis, typically seen in immunocompetent individuals as a primary infection or in immunocompromised individuals as reactivation of latent infection.
View Article and Find Full Text PDFDiscovery of potent anti-toxoplasmosis drugs from secondary metabolites in Citrus limon (lemon) leaves, supported in-silico study.
Sci Rep
January 2025
Department of Zoonotic Diseases, National Research Centre, Dokki, Giza, 12622, Egypt.
Toxoplasmosis induced by Toxoplasma gondii is a well-known health threat, that prompts fatal encephalitis increased with immunocompromised patients, in addition, it can cause chorioretinitis, microcephaly, stillbirth in the fetus and even led to death. Standard therapy uses sulfadiazine and pyrimethamine drugs revealed beneficial results during the acute stage, however, it has severe side effects. UPLC-ESI-MS/MS used to explore C.
View Article and Find Full Text PDFCongenital toxoplasmosis: Fewer clinical signs at 3 years of age over the last 15 years but stable risk of materno-fetal transmission.
Clin Infect Dis
December 2024
CHU Dijon-Bourgogne, Inserm, Université de Bourgogne, CIC1432, Module Epidémiologie Clinique, Dijon, France.
Risk and severity of congenital toxoplasmosis were estimated using data from 2,455 consecutive mother/child pairs. Clinical signs at 3 years were halved in the 177 children born since 2009 compared to 1996-2008 (OR=0.49; 95% Confidence interval 0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!